PDS Planning Inc Acquires 309 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

PDS Planning Inc raised its holdings in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 6.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,239 shares of the company’s stock after purchasing an additional 309 shares during the period. PDS Planning Inc’s holdings in Dr. Reddy’s Laboratories were worth $365,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Robeco Institutional Asset Management B.V. increased its stake in shares of Dr. Reddy’s Laboratories by 15.0% during the third quarter. Robeco Institutional Asset Management B.V. now owns 1,673,126 shares of the company’s stock valued at $111,882,000 after purchasing an additional 218,605 shares in the last quarter. Aikya Investment Management Ltd purchased a new stake in shares of Dr. Reddy’s Laboratories during the fourth quarter valued at approximately $75,850,000. Vanguard Group Inc. grew its holdings in shares of Dr. Reddy’s Laboratories by 2.0% during the third quarter. Vanguard Group Inc. now owns 1,048,152 shares of the company’s stock valued at $70,090,000 after buying an additional 20,341 shares during the last quarter. Acadian Asset Management LLC grew its holdings in shares of Dr. Reddy’s Laboratories by 26.9% during the third quarter. Acadian Asset Management LLC now owns 270,260 shares of the company’s stock valued at $18,066,000 after buying an additional 57,293 shares during the last quarter. Finally, Grantham Mayo Van Otterloo & Co. LLC grew its holdings in shares of Dr. Reddy’s Laboratories by 47.5% during the third quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 250,788 shares of the company’s stock valued at $16,770,000 after buying an additional 80,784 shares during the last quarter. Institutional investors own 14.02% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on RDY. StockNews.com upgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “strong-buy” rating in a report on Friday, April 5th. Barclays increased their price target on shares of Dr. Reddy’s Laboratories from $75.00 to $80.00 and gave the company an “overweight” rating in a report on Monday, January 29th. Finally, Jefferies Financial Group cut shares of Dr. Reddy’s Laboratories from a “buy” rating to an “underperform” rating in a report on Thursday, January 11th. One analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Dr. Reddy’s Laboratories presently has an average rating of “Hold” and a consensus price target of $80.00.

Dr. Reddy’s Laboratories Stock Performance

RDY stock traded down $0.45 on Tuesday, hitting $71.70. The company had a trading volume of 47,093 shares, compared to its average volume of 190,723. Dr. Reddy’s Laboratories Limited has a 12-month low of $53.12 and a 12-month high of $77.72. The company has a current ratio of 2.55, a quick ratio of 1.90 and a debt-to-equity ratio of 0.02. The stock’s 50-day simple moving average is $74.37 and its 200 day simple moving average is $70.31. The stock has a market cap of $11.97 billion, a price-to-earnings ratio of 19.02, a P/E/G ratio of 1.77 and a beta of 0.58.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its earnings results on Wednesday, January 31st. The company reported $0.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.11. Dr. Reddy’s Laboratories had a net margin of 19.26% and a return on equity of 20.97%. The company had revenue of $867.00 million for the quarter, compared to analysts’ expectations of $827.81 million. As a group, equities research analysts expect that Dr. Reddy’s Laboratories Limited will post 3.96 earnings per share for the current fiscal year.

Dr. Reddy’s Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.